Drug Information

Drug (ID: DG01581) and It's Reported Resistant Information

• Name: VS-5584
• Synonyms: VS-5584; 1246560-33-7; 5-(9-Isopropyl-8-methyl-2-morpholino-9H-purin-6-yl)pyrimidin-2-amine; SB2343; SB-2343; VS-5584 (SB2343); UNII-W71J4X250V; 5-(8-methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine; CHEMBL3393066; W71J4X250V; VS5584; 5-[9-Isopropyl-8-methyl-2-(morpholin-4-yl)purin-6-yl]pyrimidin-2-amine; 2-Pyrimidinamine, 5-[8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-; C17H22N8O; 2-Pyrimidinamine, 5-(8-methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl)-; SCHEMBL539098; GTPL8382; DTXSID10677328; EX-A288; HMS3652B16; BCP08247; WZB56033; 2797AH; BDBM50059635; MFCD25372027; NSC778810; NSC800991; s7016; ZINC95644685; 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine; AKOS024465057; CCG-268087; CS-1202; DB12986; NSC-778810; NSC-800991; SB 2343; SB16877; 5-[8-Methyl-2-(morpholin-4-yl)-9-(propan-2-yl)-9H-purin-6-yl]pyrimidin-2-amine; NCGC00386370-03; NCGC00386370-06; AC-33121; AS-80075; DA-46738; HY-16585; FT-0700143; SW220201-1; A857790; J-690096; Q27089164; 5-[8-Methyl-9-(1-methylethyl)-2-(4-morpholinyl)-9H-purin-6-yl]-2-pyrimidinamine; SB-2343; ; ; 5-(8-Methyl-2-morpholin-4-yl-9-propan-2-ylpurin-6-yl)pyrimidin-2-amine
• Indication:
  In total 3 Indication(s)
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]; Approved; [1]
  Malignant mesothelioma [ICD-11: 2C26]; Application submitted; [1]
  Solid tumour/cancer [ICD-11: 2A00-2F9Z]; Phase 1; [1]
• Target: Serine/threonine-protein kinase mTOR (mTOR); MTOR_HUMAN; [1]
• Formula: 3
• IsoSMILES: CC1=NC2=C(N=C(N=C2N1C(C)C)N3CCOCC3)C4=CN=C(N=C4)N
• InChI: InChI=1S/C17H22N8O/c1-10(2)25-11(3)21-14-13(12-8-19-16(18)20-9-12)22-17(23-15(14)25)24-4-6-26-7-5-24/h8-10H,4-7H2,1-3H3,(H2,18,19,20)
• InChIKey: QYBGBLQCOOISAR-UHFFFAOYSA-N
• PubChem CID: 46912230
• DrugBank ID: DB12986

Type(s) of Resistant Mechanism of This Drug

  ADTT: Aberration of the Drug's Therapeutic Target

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Colon cancer [ICD-11: 2B90]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Aberration of the Drug's Therapeutic Target (ADTT)

Key Molecule: PI3-kinase alpha (PIK3CA) [1]

• Molecule Alteration: Missense mutation; p.E542K (c.1624G>A)
• Sensitive Disease: Colon cancer [ICD-11: 2B90.1]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: SNU869 cells; Biliary tract; Homo sapiens (Human); CVCL_5101
• In Vitro Model: SNU478 cells; Biliary tract; Homo sapiens (Human); CVCL_5065
• In Vitro Model: SNU308 cells; Biliary tract; Homo sapiens (Human); CVCL_5048
• In Vitro Model: SNU245 cells; Biliary tract; Homo sapiens (Human); CVCL_5038
• In Vitro Model: SNU1196 cells; Biliary tract; Homo sapiens (Human); CVCL_5015
• In Vitro Model: SNU1079 cells; Biliary tract; Homo sapiens (Human); CVCL_5008
• In Vitro Model: SET-2 cells; Peripheral blood; Homo sapiens (Human); CVCL_2187
• In Vivo Model: Athymic BALB/c nude mouse xenograft model; Mus musculus
• Experiment for Molecule Alteration: Western blotting analysis
• Experiment for Drug Resistance: CellTiter-Glo assay
• Mechanism Description: The missense mutation p.E542K (c.1624G>A) in gene PIK3CA cause the sensitivity of VS-5584 by aberration of the drug's therapeutic target

References

• Ref 1: VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancerMol Cancer Ther. 2013 Feb;12(2):151-61. doi: 10.1158/1535-7163.MCT-12-0466. Epub 2012 Dec 27.